Application of esculetin in preparation of medicine for treating systemic lupus erythematosus

The regulation of Th17/Treg cell immune imbalance through heptalactone has solved the side effects and non-radical problems of existing SLE treatment methods, significantly improved the pathological manifestations of systemic lupus erythematosus, improved the quality of life of patients and reduced the medical burden.

CN119033768APending Publication Date: 2024-11-29ZHEJIANG CHINESE MEDICAL UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411256945.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-09
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

The existing treatments for systemic lupus erythematosus (SLE) have significant side effects and cannot cure the disease, resulting in an impact on the quality of life of patients and an increase in the burden on the health care system.

Method used

Heptalactone was used as a natural plant extract, and by regulating Th17/Treg cell immune imbalance as a potential treatment plan, it was extracted from perilla leaves and determined in in vitro cell experiments that its effective dose was 0.1μM-1μM, with a purity of ≥99. % to improve SLE condition.

Benefits of technology

Heptachloride significantly restored the immune balance of Th17/Treg cells, alleviated the pathological manifestations of SLE, such as spleen and lymph node enlargement, inflammatory cell infiltration in the kidneys, and autoantibodies, reduced inflammatory factors expression, and improved mouse models. condition.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119033768A_ABST
    Figure CN119033768A_ABST
Patent Text Reader

Abstract

The invention discloses an application of esculetin in preparation of a medicine for treating systemic lupus erythematosus. The esculetin is an active component extracted from perilla leaves, and is used for treating systemic lupus erythematosus (SLE) diseases by regulating Th17 / Treg immune imbalance. Animal experiments show that the perilla leaf extract can significantly improve the condition of lupus-like MRL / lpr model mice, glomerular inflammatory cell infiltration and deposition reduction of C3 and IgG immune complexes after intervention, the urine protein level is reduced, expression of autoantibodies and inflammatory factors in serum is reduced, and the ratio of Th17 / Treg in spleen and peripheral blood is reduced; cell experiments further prove that the active ingredient esculetin of the perilla leaves can obviously inhibit spleen Naive CD4 + T cells from differentiating to Th17 and promote the spleen Naive CD4 + T cells from differentiating to Treg, and a remarkable dose-effect relationship is shown; mechanism research shows that the esculetin can inhibit protein expression of p-STAT3 in Th17 cells and promote protein expression of Foxp3 in Treg cells, which indicates that the esculetin recovers immune balance of the Th17 / Treg cells, so that the SLE disease is improved, and a new basis is provided for treating the SLE disease.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine, and in particular to application of esculetin in preparing a medicine for treating systemic lupus erythematosus. Background Art

[0002] Systemic lupus erythematosus (SLE) is a diffuse connective tissue disease mediated by autoimmune mechanisms, characterized by the presence of multiple autoantibodies in the body, involving multiple organs / tissues such as the skin, kidneys, and blood system. The most critical pathogenesis of SLE is the destruction of the body's immune homeostasis. Regulatory T cells (Treg) are a type of cell population that has the ability to suppress immunity and maintain immune tolerance, while helper T lymphocytes (Th) 17 are a type of proinflammatory cell that can selectively express proinflammatory factors such as IL-17. TGF-β triggers the expression of Treg-specific transcription factor Forkhead box ranscription factor P3 (Foxp3), promoting the development of cells into Tregs; at the same time, Foxp3 can bind to the key transcription factor retinoic acid-related orphan nuclear receptor (RORγt), which is specific for Th17 differentiation, and helps inhibit the development of Th17. Therefore, T cell abnormalities, especially Th17 / Treg immune imbalance, are considered to be one of the most important mechanisms for the onset of SLE, and restoring the balance of Th17 / Treg responses is an important part of maintaining the body's immune homeostasis.

[0003] At present, commonly used therapeutic drugs in clinical practice include glucocorticoids, immunosuppressants, monoclonal antibodies and small molecule drugs. Although they play an important role in controlling disease activity and alleviating symptoms, they are often accompanied by significant side effects and cannot cure the disease. Glucocorticoids are the basic drugs in the treatment of SLE, which reduce inflammatory responses by suppressing the overactivity of the immune system. However, long-term use of glucocorticoids can lead to serious side effects, such as osteoporosis, increased risk of infection, hypertension, diabetes and weight gain, which greatly affect the quality of life of patients. Immunosuppressants, such as azathioprine, methotrexate and cyclophosphamide, control the progression of SLE by suppressing the activity of the immune system. However, these drugs also cause significant side effects, including bone marrow suppression, liver damage, nausea, vomiting and hair loss, and strict monitoring is required during use. In recent years, the use of monoclonal antibodies and small molecule drugs in the treatment of SLE has attracted widespread attention. These new drugs provide more precise treatment options by targeting specific immune cells or inflammatory factors. However, the high price, complex administration method and potential long-term side effects of these drugs limit their widespread application. For example, although belimumab and anifrolumab have shown certain efficacy in clinical trials, their safety and effectiveness still need to be further verified. In summary, the current SLE treatment methods, whether traditional glucocorticoids and immunosuppressants or emerging monoclonal antibodies and small molecule drugs, have certain defects and side effects. Therefore, it is of great practical significance to research and develop safer and more effective prevention and treatment programs, which will not only help improve the quality of life of SLE patients, but also reduce the burden on the medical system.

[0004] In recent years, more and more studies have focused on the potential of natural plant extracts and their active ingredients in the treatment of immune diseases. Esculetin (Es), a phenylpropanoid phenolic compound with the chemical formula C9H6O4, is an important active ingredient in the traditional Chinese herbal plant Perilla frutescens (L.) Britt. In traditional Chinese medicine, Perilla frutescens leaves are believed to have multiple pharmacological activities, including anti-inflammatory, antioxidant and immunomodulatory. Studies have shown that its active ingredient, esculetin, may play an important role in regulating the immune system and inflammatory response, such as antioxidant, anti-inflammatory, anti-tumor, sedative, protecting cells from apoptosis and necrosis, etc., making it a potential candidate for the treatment of SLE.

[0005] In the current literature reports, there is no research on the relationship between esculetin and systemic lupus erythematosus. In view of this, the present invention is proposed. Summary of the invention

[0006] The purpose of the present invention is to provide a use of esculetin in the preparation of a drug for treating systemic lupus erythematosus in view of the deficiencies of existing treatment schemes.

[0007] In order to achieve the above object, the present invention provides the use of esculetin in preparing a drug for treating systemic lupus erythematosus.

[0008] Furthermore, the in vitro cell effective dose of aesculetin is 0.1 μM-1 μM, and the purity is ≥99%.

[0009] Preferably, the in vitro cell effective dose of esculetin is 1 μM.

[0010] In some embodiments, aesculetin is extracted from perilla leaves (aesculetin is determined to be one of the effective active ingredients in perilla leaves through cell experiment screening).

[0011] Furthermore, the method for extracting aescin from perilla leaves is as follows: 60 g of perilla leaves are soaked in 600 mL of water for 30 min, boiled for 1 h, and concentrated in a water bath to 1 g of crude drug / mL to obtain a perilla leaf extract.

[0012] Furthermore, the in vitro cell effective dose of the perilla leaf extract is 10 μg / mL-100 μg / mL.

[0013] Preferably, the in vitro cell effective dose of the perilla leaf extract is 100 μg / mL.

[0014] The beneficial effects of the present invention are as follows: the aesculetin of the present invention has the function of regulating Th17 / Treg cell immune imbalance, is a natural plant extract, and is suitable for immune diseases such as systemic lupus erythematosus. BRIEF DESCRIPTION OF THE DRAWINGS

[0015] In order to more clearly illustrate the specific implementation of the present invention or the technical solution in the prior art, the following is a brief introduction to the accompanying drawings:

[0016] Figure 1Perilla leaf extract significantly improved the fluctuation of disease activity in MRL / lpr mice (*P<0.05; **P<0.01; ***P<0.001); where, (A) is the weight change of mice in each group; (B) is the spleen size of mice in each group; (C) is the lymph node size of mice in each group; (D) is the spleen index bar graph of mice in each group; (E) is the lymph node index bar graph of mice in each group; (F) is the immunofluorescence IgG expression, HE staining, and immunohistochemical C3 deposition in the kidneys of mice in each group; (G) is the quantitative analysis of the average immunofluorescence intensity of IgG in the kidneys of mice in each group; (H) is the quantitative analysis of the average optical density of C3 in the kidneys of mice in each group; (I) is the total protein in the urine of mice in each group; (J) is the expression of serum ds-DNA in mice in each group; (K) is the expression of serum IL-17A in mice in each group; (L) is the expression of serum IL-6 in mice in each group.

[0017] Figure 2 Perilla leaf extract significantly restored the immune balance of Th17 / Treg cells in the spleen and peripheral blood of MRL / lpr mice (*P<0.05; **P<0.01; ***P<0.001); (A) is the flow cytometric graph of the percentage of Treg cells in the spleen of each group of mice; (B) is the flow cytometric graph of the percentage of Th17 cells in the spleen of each group of mice; (C) is the bar graph of the percentage of Th17 cells in the spleen of each group of mice; (D) is the percentage of Treg cells in the spleen of each group of mice (E) is a bar graph of the Th17 / Treg cell ratio in the spleen of each group of mice; (F) is a flow cytometric graph of the differentiation percentage of Treg cells in the peripheral blood of each group of mice; (G) is a flow cytometric graph of the differentiation percentage of Th17 cells in the peripheral blood of each group of mice; (H) is a bar graph of the percentage of Th17 cells in the peripheral blood of each group of mice; (I) is a bar graph of the percentage of Treg cells in the peripheral blood of each group of mice; (J) is a bar graph of the Th17 / Treg cell ratio in the peripheral blood of each group of mice.

[0018] Figure 3 Perilla leaf extract inhibits spleen Naive CD4 + T cells differentiated into Th17 cells, and showed a significant dose-effect relationship (*P<0.05; **P<0.01; ***P<0.001); (A) is a flow cytometric graph of the percentage of Th17 cell differentiation in each group after induction by inflammatory agents; (B) is a bar graph of the percentage of Th17 cells in each group after induction by inflammatory agents; (C) is a flow cytometric graph of the percentage of Th17 cell differentiation under the intervention of the optimal concentration of 100 μg / mL perilla decoction; (D) is a bar graph of the percentage of Th17 cells under the intervention of the optimal concentration of 100 μg / mL perilla decoction.

[0019] Figure 4 Perilla Leaf Extract Promotes Spleen Naive CD4 +T cells differentiated into Treg cells, and showed a significant dose-effect relationship (*P<0.05; **P<0.01; ***P<0.001); (A) is a flow cytometric graph of the percentage of Treg cells in each group after induction by inflammatory agents; (B) is a bar graph of the percentage of Treg cells in each group after induction by inflammatory agents; (C) is a flow cytometric graph of the percentage of Treg cells under the intervention of the optimal concentration of 100 μg / mL perilla decoction; (D) is a bar graph of the percentage of Treg cells under the intervention of the optimal concentration of 100 μg / mL perilla decoction.

[0020] Figure 5 The mass spectrometry analysis of aescin in perilla leaf extract was performed using UPLC-Q / TOF-MS; (A) is the total ion chromatogram of the UPLC-Q / TOF-MS analysis of the standard mixture in negative mode; (B) is the ion chromatogram and retention time of aescin extracted from perilla decoction according to molecular weight.

[0021] Figure 6 Aesculetin inhibits splenic Naive CD4 + T cell Th17 cell differentiation was induced, and there was a significant dose-effect relationship (*P<0.05; **P<0.01; ***P<0.001); (A) is the flow cytometric graph of the percentage of Th17 cell differentiation in each group after induction by inflammatory agents; (B) is the bar graph of the percentage of Th17 cells in each group after induction by inflammatory agents; (C) is the flow cytometric graph of the percentage of Th17 cell differentiation under the intervention of the optimal concentration of 1 μM esculetin; (D) is the bar graph of the percentage of Th17 cells under the intervention of the optimal concentration of 1 μM esculetin.

[0022] Figure 7 The results show that esculent acid inhibits the protein and mRNA expression levels of RORγt and p-STAT3 in Th17 cells (*P<0.05; **P<0.01; ***P<0.001); (A) is the bar graph of RORγt mRNA expression in each group; (B) is the bar graph of p-STAT3 and STAT3 protein expression; (C) is the bar graph of p-STAT3 / STAT3 protein expression.

[0023] Figure 8 Esculenta promotes spleen Naive CD4 + T cells differentiated into Treg cells, and showed a significant dose-effect relationship (*P<0.05; **P<0.01; ***P<0.001); (A) is a flow cytometric graph of the percentage of Treg cells in each group after induction by inflammatory agents; (B) is a bar graph of the percentage of Treg cells in each group after induction by inflammatory agents; (C) is a flow cytometric graph of the percentage of Treg cells under the intervention of the optimal concentration of 1 μM esculetin; (D) is a bar graph of the percentage of Treg cells under the intervention of the optimal concentration of 1 μM esculetin.

[0024] Fig. 9 Aesculin promotes the expression levels of Foxp3 protein and mRNA in Treg cells (*P<0.05; **P<0.01; ***P<0.001); (A) is the bar graph of Foxp3 mRNA expression in each group; (B) is the band graph of Foxp3 protein expression; (C) is the bar graph of Foxp3 / GAPDH protein expression.

[0025] Fig.10 Schematic diagram of how esculenta improves systemic lupus erythematosus by restoring the Th17 / Treg cell immune balance. DETAILED DESCRIPTION

[0026] 1. Experimental Materials

[0027] 1. Animals

[0028] Six-week-old MRL / lpr female mice were gavaged with inflammatory agents to induce increased disease activity in order to study the effect of perilla leaf extract on improving systemic lupus erythematosus. The experimental high-lupus activity MRL / lpr mouse feeding scheme was as follows: First, 16 MRL / lpr mice were randomly divided into a model group and a perilla leaf extract treatment group according to body weight, and 8 MRL / MpJ female mice were used as a normal group. 60g of perilla leaves were soaked in 600mL of water for 30min, decocted for 1h, and concentrated to 1g of crude drug / mL in a water bath. The perilla leaf treatment group was gavaged with 0.5g of crude drug / kg mouse body weight / day, and the normal group and model group mice were given the corresponding volume of normal saline twice a day for 8 weeks.

[0029] 2. Mouse spleen primary naive CD4 + T cells

[0030] MRL / lpr lupus mice were purchased from Shanghai Slake Laboratory Animal Co., Ltd.; EasySep MouseNaive CD4 + T Cell Iso Kit was used to isolate primary Naive CD4 cells from spleen of MRL / lpr lupus mice + T cells were purchased from Canadian Stemcell, Cat.#19765.

[0031] 3. Esculenta

[0032] The purity is 99.59%, purchased from MedChemExpress, USA, Cat.#HY-N0284.

[0033] 4. Reagents

[0034] Table 1: Main reagents

[0035]

[0036]

[0037]

[0038] 2. Experimental Methods

[0039] 1. Determination of mouse spleen index and lymph node index

[0040] Fresh spleen, bilateral axillary and inguinal lymph nodes were removed, photographed, weighed, and spleen and lymph node indexes were calculated, i.e. spleen / lymph node weight (g) / body weight (g).

[0041] 2. Kidney pathology section

[0042] 2.1 H&E staining steps

[0043] Xylene (I) 3 min, xylene (II) 3 min, xylene (III) 3 min, 100% ethanol (I) 3 min, 100% ethanol (II) 1 min, 95% ethanol (I) 1 min, 95% ethanol (II) 1 min, 90% ethanol 1 min, 85% ethanol 1 min, rinse with running water for 1 min for dewaxing; hematoxylin 3 min, rinse with running water for 1 min, hydrochloric acid alcohol differentiation 10 s, rinse with running water 20 s, ammonia blueing 10 s, rinse with running water 5 min, eosin 2 min, rinse with running water 30 s, 85% ethanol 1 min, 90% ethanol 1 min, 95% ethanol (I) 1 min, 95% ethanol (II) 1 min, 100% ethanol (I) 1 min, 100% ethanol (II) 1 min, xylene (I) 1 min, xylene (II) 1 min for H&E staining, and sealing.

[0044] 2.2 Immunohistochemistry steps

[0045] The prepared sections were dewaxed, antigen repaired, incubated with primary and secondary antibodies, developed, counterstained, sealed and scanned after being made transparent.

[0046] 2.3 Immunofluorescence steps

[0047] After dewaxing, antigen repair, washing, incubation with primary and secondary antibodies were performed according to the immunohistochemistry procedures, and finally sealing and scanning were performed.

[0048] 3. Urine protein determination

[0049] The collected urine was centrifuged at 2000 rpm for 5 min, and the urine supernatant was tested using an automatic biochemical analyzer.

[0050] 4. ELISA method for detection of serum cytokines

[0051] Use ELISA kits to detect the expression of ds-DNA, IL-6, and IL-17A in serum. Take ds-DNA as an example: (1) Add 50 μL of standard samples of different concentrations. (2) Set up different sample wells, including blank control wells and test sample wells. Add 40 μL of sample diluent to the test sample well, and then add 10 μL of the test sample. (3) Then follow the instructions for adding enzyme, incubation, washing, patting dry, color development, and termination, and then place in an ELISA reader to detect the OD value at a wavelength of 450 nm.

[0052] 5. Detection of Th17 and Treg cell percentages in spleen and peripheral blood by flow cytometry

[0053] 5.1 Preparation of spleen single cell suspension

[0054] (1) Take 1 / 3 of the spleen and place it in a 70 μm cell sieve and culture dish. Add 3 mL of RPMI 1640 culture medium and grind thoroughly.

[0055] (2) Collect the filtrate from the cell sieve, centrifuge at 350g for 8 min, discard the supernatant, add 2 mL of lysate, pipette evenly, and incubate at room temperature for 5 min.

[0056] (3) Centrifuge at 350 g for 5 min, discard the supernatant, add 1 mL of PBS solution, centrifuge at 350 g for 5 min, discard the supernatant, and retain the cell pellet at the bottom.

[0057] 5.2 Preparation of peripheral blood single cell suspension

[0058] Blood was collected from the retro-orbital venous plexus of mice, 300 μL was taken into an EDTA anticoagulant tube, 3 mL of red blood cell lysis buffer was added, and the mixture was evenly mixed and allowed to stand at room temperature for 15 min, centrifuged at 400 g for 5 min, and the supernatant was discarded. Then 1 mL of PBS was added, and the mixture was centrifuged at 400 g for 5 min. After the supernatant was discarded, RPMI 1640 medium was added to obtain a single cell suspension.

[0059] 5.2 Detection of Th17 cell proportion by flow cytometry

[0060] (1) Take 250 μL of the prepared single-cell suspension to a 96-well plate, add 1 μL of each stimulation blocker, and stimulate in a 37°C oven for 4-6 hours. Collect the cells, add 1 mL of PBS, centrifuge at 500 g for 5 minutes, and discard the supernatant.

[0061] (2) Add 100 μL of prepared live / dead dye to the cell pellet, incubate in the dark for 20 min, add 1 mL of stain buffer, centrifuge at 500 g for 5 min, and discard the supernatant.

[0062] (3) Add corresponding antibodies to the single stain and sample tubes for surface staining for 20 min, centrifuge, and discard the supernatant.

[0063] (4) Add 250 μL Fixation / Permeabilization solution and incubate for 20 min in the dark. Add 1 mL Perm / Wash TM Buffer, centrifuge at 500g for 5 minutes. Add IL-17A antibody and incubate for 40 minutes in the dark. Then add 1mL Perm / Wash TM Buffer was used to wash away excess antibodies, centrifuged, and the supernatant was discarded.

[0064] (5) Add 200 μL stain buffer to resuspend the cells and detect them on the microscope.

[0065] 5.3 Flow cytometry detection of Treg cell proportion

[0066] (1) The steps of life and death and surface staining are the same as before.

[0067] (2) Nuclear destruction: According to True-Nuclear TM Transcription Factor Buffer Set Kit Instructions Prepare the fixative and nuclear disruption solution. Add 750 μL of fixative solution to each sample tube. Incubate in dark for 40 min, then add 750 μL of nuclear disruption solution, centrifuge, and remove the supernatant. Add Foxp3 antibody, incubate in dark for 40 min. Add 1 mL of membrane disruption solution, centrifuge, and remove the supernatant.

[0068] (3) Add 200 μL stain buffer to resuspend the cells and detect them on the microscope.

[0069] 6. Isolation of primary Naive CD4 from spleen of MRL / lpr lupus mice + T cells

[0070] (1) Soak the mouse in 75% ethanol for 5 min, remove the spleen in a clean bench, place it in a 70 μm cell sieve and culture dish, add 4 mL of RPMI 1640 culture medium, grind, collect the liquid under the cell sieve, centrifuge, and discard the supernatant. Resuspend in EasySep buffer and adjust the volume to 1×10 8 Pieces / mL.

[0071] (2) Add FcR blocker to a final concentration of 10 μL / mL. Transfer to a flow cytometry tube, add Isolation cocktail to a final concentration of 50 μL / mL, and incubate at room temperature for 7.5 min.

[0072] (3) Add Depletion cocktail to a final concentration of 50 μL / mL and incubate at room temperature for 2.5 min.

[0073] (4) Vortex RapidSpheres TM After 30 s, add it into the cell suspension at a final concentration of 75 μL / mL, blow evenly, and incubate at room temperature for 2.5 min.

[0074] (5) Add EasySep buffer up to 5 mL and mix thoroughly by pipetting.

[0075] (6) Place the suspension in a magnetic pole and incubate for 2.5 min.

[0076] (7) Gently tilt the magnetic pole to pour out the cell suspension into a centrifuge tube and collect the cell precipitate by centrifugation to obtain NaiveCD4 + T cells.

[0077] 7. Cell stimulation, differentiation and drug administration

[0078] 7.1 Cell Stimulation and Differentiation

[0079] (1) Add 10 μg / mL anti-CD3 antibody to each well of a 96-well plate in advance, 50 μL, at 4°C overnight. Wash the cells three times with RPMI 1640 medium before plating.

[0080] (2) Prepare T cell complete basal culture medium: RPMI 1640 culture medium + 10% FBS + 1% Penicillin-Streptomycin.

[0081] (3) Prepare Th17 cell differentiation medium: T cell complete basal medium + anti-CD28 (2 μg / mL), anti-IL-4 (10 μg / mL), anti-IFN-γ (10 μg / mL), IL-6 (100 ng / mL), TGF-β1 (5 ng / mL), IL-23 (20 ng / mL), IL-1β (10 ng / mL), 25 mM glutamine and 55 μM β-mercaptoethanol.

[0082] (4) Prepare Treg cell differentiation medium: T cell complete basal medium + anti-CD28 (2 μg / mL), 3 ng / mL TGF-β1, 10 ng / mL IL-2, 25 mM glutamine and 55 μM β-mercaptoethanol.

[0083] 7.2 Dosage regimen of Perilla leaf aqueous extract

[0084] (1) The cells were divided into 6 groups: inflammatory substance-induced model group, perilla leaf 5 μg / mL group, perilla leaf 10 μg / mL group, perilla leaf 30 μg / mL group, perilla leaf 50 μg / mL group, and perilla leaf 100 μg / mL group.

[0085] (2) Culture in a 37°C, 5% CO2 incubator for 4 days.

[0086] (3) The optimal concentration was determined by flow cytometry, and 100 μg / mL of water extract of Perilla frutescens leaves was directly applied to the sorted primary Naive CD4 + T cells were cultured in the same manner as before, and cells from the normal control group and the drug-treated group were collected for flow cytometry, Western Blot, and RT-qPCR detection.

[0087] 7.3 Esculentol Dosage Schedule

[0088] (1) The cells were divided into 4 groups: inflammatory substance-induced model group, esculetin 0.1 μM low-dose group, esculetin 0.5 μM medium-dose group, and esculetin 1 μM high-dose group.

[0089] (2) Culture in a 37°C, 5% CO2 incubator for 4 days.

[0090] (3) The optimal dosing concentration was determined by flow cytometry, and 1 μM esculetin was directly applied to Naive CD4 + T cells were cultured in the same manner as before, and cells from the normal control group and the drug-treated group were collected for flow cytometry, Western Blot, and RT-qPCR detection.

[0091] 8. Mass Spectrometry Analysis of Perilla Leaf Water Extract

[0092] The prepared perilla water extract was subjected to mass spectrometry analysis according to the following method:

[0093] Liquid phase conditions: 0.1% formic acid water and pure acetonitrile. Gradient elution process: 0-2min, 5% acetonitrile; 2-32min, 5-100% acetonitrile; 32-33min, 100% acetonitrile; 33-35min, 5% acetonitrile. Flow rate 0.3mL / min, injection volume 2μL, column temperature 35℃.

[0094] Mass spectrometry method: electrospray ESI ion source, positive and negative ion mode scanning, MSE continue full scan mode, scan time 0.2s, scan range 50-1200. Collision energy was used in MSE, low collision energy was 6V, high collision energy was 15-45eV. Real-time mass axis calibration was performed using leucine enkephalin (positive ion mode m / z 556.2771, negative ion mode m / z 554.2615).

[0095] 9. RT-qPCR detection of key transcription factors RORγt and Foxp3 mRNA transcription levels in cells

[0096] 9.1 RNA extraction:

[0097] (1) Collect cells by centrifugation at 13,000 rpm for 10 s, discard the supernatant, add 500 μL Buffer RL1, and vortex until no obvious cell clusters are present.

[0098] (2) Transfer the lysed sample to the gDNA cleanup column in the collection tube, centrifuge at 13,000 rpm for 1 min, discard the gDNA cleanup column, and collect the filtrate.

[0099] (3) Add 0.5 times the volume of anhydrous ethanol to the filtrate and mix immediately by pipetting.

[0100] (4) Add the above mixture to the RNase-free adsorption column in the collection tube, centrifuge at 13000 rpm for 30 seconds, and discard the filtrate.

[0101] (5) Place the adsorption column back into the collection tube, add 700 μL of PR2, centrifuge for 30 seconds, and remove the filtrate.

[0102] (6) Add 500 μL of WB2, centrifuge, and remove the filtrate. Repeat this operation once.

[0103] (7) Centrifuge the empty tube to remove the remaining rinse solution.

[0104] (8) Take out the RNase-free adsorption column and place it in a 1.5 mL RNase-free centrifuge tube. Add 50 μL of RNase-free dd H2O to the middle part of the adsorption column. After standing at room temperature for 2 minutes, centrifuge at 13,000 rpm for 1 minute to elute the RNA.

[0105] (9) The extracted RNA can be used directly in downstream experiments or stored at -80°C.

[0106] 9.2 Reverse transcription of total RNA into cDNA

[0107] (1) Reverse transcription reaction system / negative control system

[0108] On ice, add the following components to an RNase-free PCR tube, mix well, and centrifuge briefly:

[0109] Table 2: Reverse transcription reaction system (20 μL)

[0110]

[0111] (2) Reverse transcription reaction conditions:

[0112] Table 3: Reverse transcription reaction conditions

[0113]

[0114] 9.3 Perform qPCR experiments according to the relevant instructions

[0115] Table 4: qPCR amplification primer sequences

[0116]

[0117] Table 5: qPCR reaction system (20 μL)

[0118]

[0119] Reaction conditions: 95°C for 2 min, 95°C for 15 s, 60°C for 50 s, 40 cycles.

[0120] 10. Western Blot was used to detect the expression levels of transcription factors RORγt and Foxp3 proteins in each group of cells

[0121] Prepare relevant solutions and reagents according to the instructions. Collect cells into a 1.5mL centrifuge tube and add the corresponding protein lysis buffer for protein lysis according to the instructions. Add 5×SDS-PAGE protein loading buffer to the protein supernatant obtained after lysis, mix well, heat in a metal bath at 100℃ for 10min, and freeze at -80℃ for later use. Prepare gel, electrophoresis and transfer membrane according to the instructions of the kit. Block the PVDF membrane with the prepared 5% skimmed milk powder at room temperature for 1.5h, wash three times, add the corresponding primary antibody and incubate overnight. Wash, add the corresponding secondary antibody, incubate in the dark for 1.5h, and wash. Scan the membrane and use ImageJ software for grayscale value analysis. The expression amount of the target protein = grayscale value of the target protein / grayscale value of the internal reference protein.

[0122] 11. Statistical analysis

[0123] SPSS26.0 software was used for statistical analysis of experimental data, and GraphPad Prism 9.3.1 software was used for drawing. The measured data were expressed as mean ± standard error (M ± SEM). Through normality analysis, the differences between the groups were compared using ANOVA one-way analysis of variance if they were in accordance with normal distribution, and P < 0.05 was considered statistically significant. Immunohistochemistry and immunofluorescence were semi-quantitatively analyzed using ImageJ software.

[0124] 3. Experimental Results

[0125] 1. Perilla leaf extract can improve disease manifestations in lupus-like model mice

[0126] In order to detect the effect of perilla leaf extract on the manifestations of lupus-like model mice, the present invention first observed through body weight measurement that perilla leaf extract intervention could alleviate the weight gain of model mice, but the above differences were not statistically significant ( Figure 1A). By calculating the enlargement index of the spleen and lymph nodes of mice, it was found that the spleen of the model group was significantly enlarged compared with the normal group (P<0.001). Compared with the model group, the enlargement of the spleen and lymph nodes of mice after intervention with perilla leaf extract was significantly improved (P<0.05), indicating that it can effectively alleviate the increase of the spleen and lymph node index in lupus-like model mice ( Figure 1 BE). Pathological results showed that compared with the normal group, the mice in the model group had significant renal pathological changes, such as increased glomerular volume, increased inflammatory cell infiltration, and large amounts of C3 and IgG deposition in the glomeruli (P<0.001). However, after intervention with perilla leaf extract, glomerular inflammatory cell infiltration, IgG and C3 deposition were significantly reduced (P<0.01, Figure 1 FH). In addition, the urine supernatant was tested with an automatic biochemical analyzer and found that the urine protein in the model group was significantly higher than that in the normal group (P<0.05). After treatment, the urine protein level showed a significant downward trend (P<0.05), indicating that the treatment with perilla leaf extract can alleviate the renal damage in lupus-like model mice ( Figure 1 I). ELISA analysis revealed that the anti-ds-DNA content in the serum of the model group was significantly higher than that of the normal group (P<0.001), and the level of anti-ds-DNA autoantibodies in the serum of mice decreased significantly after treatment (P<0.01), indicating that the perilla leaf extract can alleviate the overexpression of autoantibodies in the high activity lupus model mice ( Figure 1 J). At the same time, the expression of serum inflammatory factors in mice was detected, and it was found that the expression levels of IL-17A and IL-6 in the model group were significantly higher than those in the normal group (P<0.001), and the serum IL-17A content after treatment was significantly lower than that in the model group (P<0.001, Figure 1 K), in addition, the IL-6 content also showed a significant downward trend compared with the model group (P<0.05, Figure 1 L).

[0127] 2. Perilla leaf extract significantly restored the immune balance of Th17 / Treg cells in the spleen and peripheral blood of lupus-like model mice

[0128] Flow cytometry was used to detect the expression of Th17 and Treg cells in the spleen of each group of mice. Compared with the normal group, the proportion of Th17 cells in the spleen of the model group mice was significantly increased (P<0.001), the Treg cells were significantly decreased (P<0.001), and the Th17 / Treg ratio also increased accordingly (P<0.001). After intervention treatment with perilla leaf extract, it was found that the proportion of Th17 cells in the spleen of mice was significantly decreased compared with the model group (P<0.001), and the proportion of Treg cells was significantly increased compared with the shrimp group (P<0.05), thereby significantly reducing the Th17 / Treg ratio in the spleen of mice (P<0.001), and restoring the Th17 / Treg immune balance in mice to a certain extent ( Figure 2 AE). In addition, flow cytometry was used to detect the ratio of Th17 and Treg cells in the peripheral blood of mice. It was found that compared with the normal group, the Th17 / Treg ratio in the peripheral blood of the model group mice increased significantly (P<0.001). Perilla leaf extract intervention could inhibit the expression of Th17 cells and significantly promote the expression of Treg cells (P<0.01), thereby reducing the Th17 / Treg ratio (P<0.01) and restoring the immune balance of lupus-like model mice ( Figure 2 FJ).

[0129] 3. In vitro experiments verified that perilla leaf extract can regulate the differentiation of spleen Th17 cells

[0130] In order to further clarify the regulatory effect of perilla leaf extract on Th17 / Treg immune imbalance in lupus-like model mice, the present invention first studied the regulatory effect of perilla leaf extract on the in vitro differentiation of Th17 cells ( Figure 3 AD). Through intervention at different concentrations, it was found that perilla leaf extract could significantly inhibit the differentiation of Th17 cells aggravated by inflammatory substances in the model group (*P<0.05, **P<0.01, ***P<0.001), and it was dose-dependent. The higher the concentration, the stronger the effect of inhibiting Th17 cell differentiation. Therefore, the optimal drug concentration of 100 μg / mL perilla leaf extract was selected for subsequent experiments. It was finally found that when perilla leaf extract acted directly on Th17 cells alone, Th17 cell differentiation was also inhibited compared with the normal control group (P<0.05), indicating that perilla leaf extract can directly affect Th17 cells and inhibit their differentiation.

[0131] 4. In vitro experiments verified that perilla leaf extract can regulate the differentiation of splenic Treg cells

[0132] After intervention with different concentrations of perilla leaf extract, the Treg cell differentiation level that was significantly suppressed in the model group was restored in a dose-dependent manner (P<0.001). The higher the concentration of perilla leaf extract, the more Treg cells differentiated ( Figure 4 AB). However, compared with the normal control group, intervention with perilla leaf extract alone could not significantly promote the differentiation of Treg cells ( Figure 4 CD).

[0133] 5. Mass spectrometry analysis of aescin in perilla leaf extract using UPLC-Q / TOF-MS

[0134] Liquid chromatography-mass spectrometry and standard samples were used to identify the active compounds of esculetin in the extract of Perilla frutescens leaves. Figure 5 A is the ion chromatogram of the standard mixture in negative ion mode. Figure 5B is the ion current diagram extracted according to the molecular weight of esculetin compound, combined with the retention time, indicating that the perilla leaf extract contains the active monomer component esculetin.

[0135] 6. Esculenta can regulate the differentiation of spleen Th17 cells

[0136] Aesculetin is one of the main components of phenylpropanoid compounds in Perilla leaves. In vitro cell experiments showed that compared with the model group, aesculetin intervention could significantly inhibit Th17 cell differentiation in a dose-dependent manner (P<0.05, P<0.01, Figure 6 AB). Therefore, the optimal drug concentration of 1 μM aesculetin was selected for subsequent experiments. It was finally found that when aesculetin acted directly on Th17 cells alone, the differentiation of Th17 cells was also inhibited compared with the normal control group (P<0.05), indicating that aesculetin can directly affect Th17 cells and inhibit their differentiation ( Figure 6 CD).

[0137] 7. Western Blot and RT-qPCR detection of Th17 cell-related protein and mRNA expression

[0138] Western Blot and RT-qPCR were used to detect the expression levels of p-STAT3 protein and RORγt mRNA in Th17 cells after esculetin intervention. The results showed that compared with the normal control group, esculetin intervention could inhibit the expression of RORγt mRNA in Th17 cells to a certain extent ( Figure 7 A), and could significantly inhibit the phosphorylation level of STAT3 protein in Th17 cells (P<0.05, Figure 7 BC).

[0139] 8. Esculenta can regulate the differentiation of splenic Treg cells

[0140] In addition, compared with the model group, aesculetin could also significantly promote Treg cell differentiation. With the increase of drug concentration, the proportion of Treg cells increased (P<0.05, P<0.001, Figure 8 AB). Then, the optimal dosage concentration of 1 μM aesculetin was selected to directly act on Treg cells. Compared with the normal control group, the differentiation of Treg cells increased significantly (P<0.05), indicating that aesculetin can directly affect Treg cells and promote their differentiation ( Figure 8 CD).

[0141] 9. Western Blot and RT-qPCR detection of Treg cell-related protein and mRNA expression

[0142] Western Blot and RT-qPCR were used to detect the expression of Foxp3 protein and mRNA in Treg cells after esculetin intervention. The results showed that compared with the normal control group, esculetin intervention had no significant effect on the expression of Foxp3 mRNA in Treg cells ( Fig. 9 A), but could significantly promote the expression of Foxp3 protein in Treg cells (P<0.05, Fig. 9 BC).

Claims

1. Application of esculetin in the preparation of drugs for the treatment of systemic lupus erythematosus.

2. The use according to claim 1, characterized in that: The in vitro effective cell dose of esculetin is 0.1μM-1μM, and the purity is ≥99%.

3. The use according to claim 2, characterized in that: The in vitro effective dose of esculetin for cells is 1 μM.

4. The use according to claim 1, characterized in that: Escin is extracted from Perilla leaves.

5. The use according to claim 4, characterized in that: The method for extracting aescin from perilla leaves is as follows: 60 g of perilla leaves are soaked in 600 mL of water for 30 minutes, boiled for 1 hour, and concentrated in a water bath to 1 g of crude drug / mL to obtain a perilla leaf extract.

6. The use according to claim 5, characterized in that: The in vitro cell effective dosage of the perilla leaf extract is 10 μg / mL-100 μg / mL.

7. The use according to claim 6, characterized in that: The in vitro cell effective dose of the perilla leaf extract is 100 μg / mL.